Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled study of XC2309 tablets in duodenal ulcer
CTR20243235Phase 2Completed
- Sponsor
- Zhejiang Medicine Co., Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XC2309 in duodenal ulcer, sponsored by Zhejiang Medicine Co., Ltd.. Started Aug 2024; status: completed.
02
Drugs
XC2309
03
Conditions
duodenal ulcer
Beyond the preview
Go deeper on CTR20243235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243235.